Clozapine monitoring at a specialised psychiatric hospital: A retrospective chart review

Background: Clozapine is the only Food and Drug Administration (FDA) and National Institute for Care and Excellence (NICE) approved drug for treatment-resistant schizophrenia (TRS). Its potentially life-threatening haematological side effects of neutropaenia and agranulocytosis mandate rigorous moni...

Descripció completa

Dades bibliogràfiques

Autors principals:	Michelle V. Daniels, Suvira Ramlall
Format:	Artigo
Idioma:	Inglês
Publicat:	AOSIS 2023-10-01
Col·lecció:	South African Journal of Psychiatry
Matèries:	clozapine monitoring guidelines clozapine monitoring guidelines in south africa treatment-resistant schizophrenia benign ethnic neutropaenia benign familial neutropaenia clozapine-induced neutropaenia clozapine-induced agranulocytosis
Accés en línia:	https://sajp.org.za/index.php/sajp/article/view/2039
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!